An overview of current delivery systems in cancer gene therapy

Journal of Controlled Release

Volumn 94, Issue 1, 2004, Pages 1-14

  El Aneed, Anas ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cancer gene therapy; Cationic liposomes; Gene delivery; Non viral vectors; Viral vectors

Indexed keywords

CATIONIC POLYMERIZATION; CELLS; GENETIC ENGINEERING; IMMUNOLOGY; POLYPEPTIDES; TUMORS; VECTORS; VIRUSES;

GENE DELIVERY SYSTEM; GENE THERAPY;

DRUG DOSAGE;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 3BETA [N (N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; ADENOVIRUS VECTOR; CHITOSAN; DRUG CARRIER; LIPOSOME; PACLITAXEL; PARVOVIRUS VECTOR; PEPTIDE; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CELL TYPE; DNA TRANSFECTION; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; ENCAPSULATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS VECTOR; HOST CELL; HYDROPHILICITY; IMMUNOGENICITY; MEDICAL RESEARCH; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POXVIRUS VECTOR; PRIORITY JOURNAL; RECOMBINANT GENE; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY; TRANSGENE; TUMOR; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

EID: 0347365764     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.09.013     Document Type: Review

References (151)

1. Breyer B., Jiang W., Cheng H., Zhou L., Paul R., Feng T., He T.C. Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther. 1:2001;149-162.
2. Bertram J.S. The molecular biology of cancer. Mol. Aspects Med. 21:2000;167-223.
3. Kirn D., Niculescu-Duvaz I., Hallden G., Springer C.J. The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med. 8(4 Suppl.):2002;S68-S73.
4. Mullen C.A. Metabolic suicide genes in gene therapy. Pharmacol. Ther. 63:1994;199-207.
5. Oettgen H.F., Old L.J. The history of cancer immunotherapy. DeVita V.T., Hellmann S., Rosenberg S.A. Biological Therapy of Cancer: Principles and Practice. 1991;87-119 JB Lppincott, Philadelphia.
6. Shi F., Rakhmilevich A.L., Heise C.P., Oshikawa K., Sondel P.M., Yang N.S., Mahvi M.D. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol. Cancer Ther. 1:2002;949-957.
7. Barajas M., Mazzolini G., Genove G., Bilbao R., Narvaiza I., Schmitz V., Sangro B., Melero I., Qian C., Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology. 33:2001;52-61.
8. Walther W., Stein U., Fichtner I., Voss C., Schmidt T., Schleef M., Nellessen T., Schlag P.M. Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol. Biotechnol. 21:2002;105-115.
9. Hanke P., Serwe M., Dombrowski F., Sauerbruch T., Caselmann W.H. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther. 9:2002;346-355.
10. Conry R.M., White S.A., Fultz P.N., Khazaeli M.B., Strong T.V., Allen K.O., Barlow D.L., Moore S.E., Coan P.N., Davis I., Curiel D.T., LoBuglio A.F. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin. Cancer Res. 4:1998;2903-2912.
11. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12:1995;825-830.
12. Cusack J.C. Jr., Tanabe K.K. Introduction to cancer gene therapy. Surg. Oncol. Clin. N. Am. 11:2002;497-519.
13. Wei C.M., Gibson M., Spear P.G., Scolnick E.M. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J. Virol. 39:1981;935-944.
14. Shimotohno K., Temin H.M. Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell. 26:1981;67-77.
15. Barzon L., Bonaguro R., Castagliuolo I., Chilosi M., Franchin E., Del Vecchio C., Giaretta I., Boscaro M., Palu G. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur. J. Endocrinol. 148:2003;73-80.
16. Saudemont A., Buffenoir G., Denys A., Desreumaux P., Jouy N., Hetuin D., Bauters F., Fenaux P., Quesnel B. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia. 16:2002;1637-1644.
17. Caruso M., Pham-Nguyen K., Kwong Y.L., Xu B., Kosai K.I., Finegold M., Woo S.L., Chen S.H. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11302-11306.
18. Fillat C., Carrio M., Cascante A., Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr. Gene Ther. 3:2003;13-26.
19. Dubowchik G.M., Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83:1999;67-123.
20. Lewis P.F., Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68:1994;510-516.
21. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 10:1994;4239-4242. (1990).
22. Buchschacher G.L. Jr., Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood. 95:2000;2499-2504.
23. Indraccolo S., Habeler W., Tisato V., Stievano L., Piovan E., Tosello V., Esposito G., Wagner R., Uberla K., Chieco-Bianchi L., Amadori A. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res. 62:2002;6099-6107.
24. Pang S., Kang M.K., Kung S., Yu D., Lee A., Poon B., Chen I.S.Y., Lindemann B., Park N. Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin. Cancer Res. 7:2001;3567-3573.
25. Solly S.K., Trajcevski S., Frisen C., Holzer G.W., Nelson E., Clerc B., Abordo-Adesida E., Castro M., Lowenstein P., Klatzmann D. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 10:2003;30-39.
26. Logg C.R., Logg A., Matusik R.J., Bochner B.H., Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol. 76:2002;12783-12791.
27. Li Q., Kay M.A., Finegold M., Stratford-Perricaudet L.D., Woo S.L. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4:1993;403-409.
28. Quantin B., Perricaudet L.D., Tajbakhsh S., Mandel J.L. Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 89:1992;2581-2584.
29. Doerfler W. Foreign DNA in Mammalian Systems. 2000;WILEY-VCH, Weinheim, Germany.
30. Engelhardt J.F., Ye X., Doranz B., Wilson J.M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U. S. A. 91:1994;6196-6200.
31. Harrington K.J., Spitzweg C., Bateman A.R., Morris J.C., Vile R.G. Gene therapy for prostate cancer: current status and future prospects. J. Urol. 166:2001;1220-1233.
32. Kelly T.J. Jr. Adenovirus DNA replication. Ginsberg H.S. The Adenoviruses. 1984;271-308 Plenum, New York.
33. Swisher S.G., Roth J.A., Komaki R., Gu J., Lee J.J., Hicks M., Ro J.Y., Hong W.K., Merritt J.A., Ahrar K., Atkinson N.E., Correa A.M., Dolormente M., Dreiling L., El-Naggar A.K., Fossella F., Francisco R., Glisson B., Grammer S., Herbst R., Huaringa A., Kemp B., Khuri F.R., Kurie J.M., Liao Z., McDonnell T.J., Morice R., Morello F., Munden R., Papadimitrakopoulou V., Pisters K.M., Putnam J.B. Jr., Sarabia A.J., Shelton T., Stevens C., Shin D.M., Smythe W.R., Vaporciyan A.A., Walsh G.L., Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9:2003;93-101.
34. Roy I., Holle L., Song W., Holle E., Wagner T., Yu X. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro. Anticancer Res. 22:2002;3185-3189.
35. Anderson S.C., Johnson D.E., Engler H., Hancock W., Huang W., Wills K.N., Gregory R.J., Sutjipto S., Wen S.F., Lofgren S., Shepard H.M., Maneval D.C. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of recombinant adenovirus. Clin. Cancer. Res. 4:1998;1649-1659.
36. Ragot T., Vincent N., Chafey P., Vigne E., Gilgenkrantz H., Couton D., Cartaud J., Briand P., Kaplan J.C., Perricaudet M., Khan A. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature. 361:1993;647-650.
37. Mack C.A., Song W.R., Carpenter H., Wickham T.J., Kovesdi I., Harvey B.G., Magovern C.J., Isom O.W., Rosengart T., Falck-Pedersen E., Hackett N.R., Crystal R.G., Mastrangeli A. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8:1997;99-109.
38. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4407-4411.
39. Bramson J.L., Hitt M., Gauldie J., Graham F.L. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4:1997;1069-1076.
40. Raper S.E., Yudkoff M., Chirmule N., Gao G.P., Nunes F., Haskal Z.J., Furth E.E., Propert K.J., Robinson M.B., Magosin S., Simoes H., Speicher L., Hughes J., Tazelaar J., Wivel N.A., Wilson J.M., Batshaw M.L. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 13:2002;163-175.
41. Vlachaki M.T., Hernandez-Garcia A., Ittmann M., Chhikara M., Aguilar L.K., Zhu X., Teh B.S., Butler E.B., Woo S., Thompson T.C., Barrera-Saldana H., Aguilar-Cordova E., The B.S. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol. Ther. 6:2002;342-348.
42. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., Hawkins L., Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6:2000;1134-1139.
43. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:1997;2559-2563.
44. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
45. Corey L., Spear P.G. Infections with herpes simplex viruses (2). N. Engl. J. Med. 314:1986;749-757.
46. Parker J.N., Gillespie G.Y., Love C.E., Randall S., Whitley R.J., Markert J.M. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2208-2213.
47. Wu N., Watkins S.C., Schaffer P.A., DeLuca N.A. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4 ICP27 and ICP22. J. Virol. 70:1996;6358-6369.
48. Marconi P., Krisky D., Oligino T., Poliani P.L., Ramakrishnan R., Goins W.F., Fink D.J., Glorioso J.C. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11319-11320.
49. Toda M., Martuza R.L., Rabkin S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther. 2:2000;324-329.
50. D'Angelica M., Karpoff H., Halterman M., Ellis J., Klimstra D., Edelstein D., Brownlee M., Federoff H., Fong Y. In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol. Immunother. 47:1999;265-271.
51. Latchman D.S. Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene. 264:2001;1-9.
52. Moriuchi S., Wolfe D., Tamura M., Yoshimine T., Miura F., Cohen J.B., Glorioso J.C. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther. 9:2002;584-591.
53. Jain K.K. Textbook of Gene Therapy. 1998;Hogrefe and Huber Publishers, Gottingen, Germany.
54. Samulski R.J., Zhu X., Xiao X., Brook J.D., Housman D.E., Epstein N., Hunter L.A. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10:1991;3941-3950.
55. Buller R.M., Janik J.E., Sebring E.D., Rose J.A. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J. Virol. 40:1981;241-247.
56. Janik J.E., Huston M.M., Cho K., Rose J.A. Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VA I RNA. Virology. 168:1989;320-329.
57. Yakinoglu A.O., Heilbronn R., Burkle A., Schlehofer J.R., zur Hausen H. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res. 48:1988;3123-3129.
58. Alexander I.E., Russell D.W., Miller A.D. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J. Virol. 68:1994;8282-8287.
59. Alexander I.E., Russell D.W., Spence A.M., Miller A.D. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum. Gene Ther. 7:1996;841-850.
60. Kanazawa T., Mizukami H., Okada T., Hanazono Y., Kume A., Nishino H., Takeuchi K., Kitamura K., Ichimura K., Ozawa K. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther. 10:2003;51-58.
61. Ponnazhagan S., Curiel D.T., Shaw D.R., Alvarez R.D., Siegal G.P. Adeno-associated virus for cancer gene therapy. Cancer Res. 61:2001;6313-6321.
62. Su H., Lu R., Chang J.C., Kan Y.W. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc. Natl. Acad. Sci. U. S. A. 94:1997;13891-13896.
63. Vermeij J., Zeinoun Z., Neyns B., Teugels E., Bourgain C., De Greve J. Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. Br. J. Cancer. 85:2001;1592-1599.
64. Smith G.L., Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 25:1983;21-28.
65. Gomella L.G., Mastrangelo M.J., McCue P.A., Maguire H.C. Jr., Mulholland S.G., Lattime E.C. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 166:2001;1291-1295.
66. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11349-11353.
67. Qin H., Valentino J., Manna S., Tripathi P.K., Bhattacharya-Chatterjee M., Foon K.A., O'Malley B.W. Jr., Chatterjee S.K. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol. Ther. 4:2001;551-558.
68. Peplinski G.R., Tsung K., Meko J.B., Norton J.A. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery. 118:1995;185-191.
69. Kaufman H.L., Flanagan K., Lee C.S., Perretta D.J., Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine. 20:2002;1862-1869.
70. Behr J.P. Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjug. Chem. 5:1994;382-389.
71. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. Versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7297-7301.
72. Kichler A., Leborgne C., Coeytaux E., Danos O. Polyethylenimine-mediated gene delivery: a mechanistic study. J. Gene Med. 3:2001;135-144.
73. Klemm A.R., Young D., Lloyd J.B. Effects of polyethyleneimine on endocytosis and lysosome stability. Biochem. Pharmacol. 56:1998;41-46.
74. Kunath K., von Harpe A., Fischer D., Petersen H., Bickel U., Voigt K., Kissel T. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release. 89:2003;113-125.
75. Kircheis R., Schuller S., Brunner S., Ogris M., Heider K.H., Zauner W., Wagner E. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gene Med. 1:1999;111-120.
76. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16:1999;1273-1279.
77. Wightman L., Kircheis R., Rossler V., Carotta S., Ruzicka R., Kursa M., Wanger E. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. 3:2001;362-372.
78. Chollet P., Favrot M.C., Hurbin A., Coll J.L. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J. Gene Med. 4:2002;84-91.
79. Wu G.Y., Wu C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262:1987;4429-4432.
80. Ward C.M., Read M.L., Seymour L.W. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood. 97:2001;2221-2229.
81. Dash P.R., Read M.L., Barrett L.B., Wolfert M.A., Seymour L.W. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6:1999;643-650.
82. Pouton C.W., Lucas P., Thomas B.J., Uduehi A.N., Milroy D.A., Moss S.H. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control. Release. 53:1998;289-299.
83. Shewring L., Collins L., Lightman S.L., Hart S., Gustafsson K., Fabre J.W. A nonviral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins. Transplantation. 64:1997;763-769.
84. Lee H., Jeong J.H., Park T.G. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J. Control. Release. 79:2002;283-291.
85. Wagner E., Plank C., Zatloukal K., Cotton M., Birnsteil M.L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferring-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. U. S. A. 89:1992;7934-7938.
86. Brown M.D., Schatzlein A., Brownlie A., Jack V., Wang W., Tetley L., Gray A.I., Uchegbu I.F. Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. Bioconjug. Chem. 11:2000;880-891.
87. Ward C.M., Pechar M., Oupicky D., Ulbrich K., Seymour L.W. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J. Gene Med. 4:2002;536-547.
88. Suh W., Chung J.K., Park S.H., Kim S.W. Anti-JL1 antibody-conjugated poly(L-lysine) for targeted gene delivery to leukemia T cells. J. Control. Release. 72:2001;171-178.
89. Faraasen S., Voros J., Csucs G., Textor M., Merkle H.P., Walter E. Ligand-specific targeting of microspheres to phagocytes by surface modification with poly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm. Res. 20:2003;237-246.
90. Nah J.W., Yu L., Han S.O., Ahn C.H., Kim S.W. Artery wall binding peptide-poly(ethylene glycol)-grafted-poly(L-lysine)-based gene delivery to artery wall cells. J. Control. Release. 78:2002;273-284.
91. Pichon C., Goncalves C., Midoux P. Histidine-rich peptides and polymers for nucleic acids delivery. Adv. Drug Deliv. Rev. 53:2001;75-94.
92. Midoux P., Monsigny M. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug. Chem. 10:1999;406-411.
93. Mannisto M., Vanderkerken S., Toncheva V., Elomaa M., Ruponen M., Schacht E., Urtti A. Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J. Control. Release. 83:2002;169-182.
94. Nishikawa M., Takemura S., Takakura Y., Hashida M. Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. J. Pharmacol. Exp. Ther. 287:1998;408-415.
95. Wolfert M.A., Dash P.R., Nazarova O., Oupicky D., Seymour L.W., Smart S., Strohalm J., Ulbrich K. Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA. Bioconjug. Chem. 10:1999;993-1004.
96. Koping-Hoggard M., Mel'nikovaS Y.S., Varum K.M., Lindman B., Artursson P. Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo. J. Gene Med. 5:2003;130-141.
97. Lee M., Nah J.W., Kwon Y., Koh J.J., Ko K.S., Kim S.W. Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm. Res. 18:2001;427-431.
98. Vincent L., Varet J., Pille J.Y., Bompais H., Opolon P., Maksimenko A., Malvy C., Mirshahi M., Lu H., Vannier J.P., Soria C., Li H. Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies. Int. J. Cancer. 105:2003;419-429.
99. Bielinska A.U., Yen A., Wu H.L., Zahos K.M., Sun R., Weiner N.D., Baker J.R. Jr., Roessler B.J. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials. 21:2000;877-887.
100. Read M.L., Bremner K.H., Oupick D., Green N.K., Searle P.F., Seymour L.W. Vectors based on reducible polycations facilitate intracellular release of nucleic acids. J. Gene Med. 5:2003;232-245.
101. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., Szoka F.C. Jr. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry. 36:1997;3008-3017.
102. Niidome T., Takaji K., Urakawa M., Ohmori N., Wada A., Hirayama T., Aoyagi H. Chain length of cationic alpha-helical peptide sufficient for gene delivery into cells. Bioconjug. Chem. 10:1999;773-780.
103. Haines A.M., Irvine A.S., Mountain A., Charlesworth J., Farrow N.A., Husain R.D., Hyde H., Ketteringham H., McDermott R.H., Mulcahy A.F., Mustoe T.L., Reid S.C., Rouquette M., Shaw J.C., Thatcher D.R., Welsh J.H., Williams D.E., Zauner W., Phillips R.O. CL22-a novel cationic peptide for efficient transfection of mammalian cells. Gene Ther. 8:2001;99-110.
104. Ohmori N., Niidome T., Kiyota T., Lee S., Sugihara G., Wada A., Hirayama T., Aoyagi H. Importance of hydrophobic region in amphiphilic structures of alpha-helical peptides for their gene transfer-ability into cells. Biochem. Biophys. Res. Commun. 245:1998;259-265.
105. McKenzie D.L., Smiley E., Kwok K.Y., Rice K.G. Low molecular weight disulfide cross-linking peptides as nonviral gene delivery carriers. Bioconjug. Chem. 11:2000;901-909.
106. Niidome T., Urakawa M., Sato H., Takahara Y., Anai T., Hatakayama T., Wada A., Hirayama T., Aoyagi H. Gene transfer into hepatoma cells mediated by galactose-modified alpha-helical peptides. Biomaterials. 21:2000;1811-1819.
107. Kim H.H., Lee W.S., Yang J.M., Shin S. Basic peptide system for efficient delivery of foreign genes. Biochim. Biophys. Acta. 1640:2003;129-136.
108. Plank C., Tang M.X., Wolfe A.R., Szoka F.C. Jr. Branched cationic eptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum. Gene Ther. 10:1999;319-332.
109. Rittner K., Benavente A., Bompard-Sorlet A., Heitz F., Divita G., Brasseur R., Jacobs E. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol. Ther. 5:2002;104-114.
110. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7413-7417.
111. Yi S.W., Yune T.Y., Kim T.W., Chung H., Choi Y.W., Kwon I.C., Lee E.B., Jeong S.Y. A cationic lipid emulsion/DNA complex as a physically stable and serum-resistant gene delivery system. Pharm. Res. 17:2000;314-320.
112. Choi B.Y., Chung J.W., Park J.H., Kim K.H., Kim Y.I., Koh Y.H., Kwon J.W., Lee K.H., Choi H.J., Kim T.W., Kim Y.J., Chung H., Kwon I.C., Jeong S.Y. Gene delivery to the rat liver using cationic lipid emulsion/DNA complex: comparison between intra-arterial, intraportal and intravenous administration. Korean J. Radiol. 3:2002;194-198.
113. Lasic D.D. Liposomes in Gene Delivery. 1997;CRC Press, Boca Raton, FL.
114. Gao H., Hui K.M. Synthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivatives. Gene Ther. 8:2001;855-863.
115. Ewert K., Ahmad A., Evans H.M., Schmidt H.W., Safinya C.R. Efficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene delivery. J. Med. Chem. 45:2002;5023-5029.
116. Behr J.P., Demeneix B., Leffler J.P., Perez-Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc. Natl. Acad. Sci. U. S. A. 86:1989;6982-6986.
117. Huang C.H. Studies on phosphatidylcholine vesicles. Formation and physical characterization. Biochemistry. 8:1969;344-351.
118. Jiskoot W., Teerlink T., Beuvery E.C., Crommelin D.J. Preparation of liposomes via detergent removal from mixed micelles by dilution. The effect of bilayer composition and process parameters on liposome characteristics. Pharm. Weekbl. Sci. Ed. 8:1986;259-265.
119. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped violume and ability to maintain a membrane potential. Biochim. Biophys. Acta. 812:1985;55-65.
120. Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta. 858:1986;161-168.
121. Radler J.O., Koltover I., Salditt T., Safinya C.R. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science. 275:1997;810-814.
122. Sternberg B., Sorgi F.L., Huang L. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett. 356:1994;361-366.
123. Almofti M.R., Harashima H., Shinohara Y., Almofti A., Baba Y., Kiwada H. Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization. Arch. Biochem. Biophys. 410:2003;246-253.
124. Pedroso de Lima M.C., Simoes S., Pires P., Faneca H., Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv. Drug Deliv. Rev. 47:2001;277-294.
125. Ross P.C., Hui S.W. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther. 6:1999;651-659.
126. Zou Y., Zong G., Ling Y.H., Perez-Soler R. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther. 7:2000;683-696.
127. Balasubramaniam R.P., Bennett M.J., Aberle A.M., Malone J.G., Nantz M.H., Malone R.W. Structural and functional analysis of cationic transfection lipids: the hydrophobic domain. Gene Ther. 3:1996;163-172.
128. Gorman C.M., Aikawa M., Fox B., Fox E., Lapuz C., Michaud B., Nguyen H., Roche E., Sawa T., Wiener-Kronish J.P. Efficient in in vivo delivery of DNA to pulmonary cells using the novel lipid EDMPC. Gene Ther. 4:1997;983-992.
129. Lee E.R., Marshall J., Siegel C.S., Jiang C., Yew N.S., Nichols M.R., Nietupski J.B., Ziegler R.J., Lane M.B., Wang K.X., Wan N.C., Scheule R.K., Harris D.J., Smith A.E., Cheng S.H. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7:1996;1701-1717.
130. Solodin I., Brown C.S., Bruno M.S., Chow C.Y., Jang E.H., Debs R.J., Heath T.D. A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery. Biochemistry. 34:1995;13537-13544.
131. Liu Y., Mounkes L.C., Liggitt H.D., Brown C.S., Solodin I., Debs R., Heath T.D. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15:1997;167-173.
132. Bennett M.J., Nantz M.H., Balasubramaniam R.P., Gruenert D.C., Malone R.W. Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells. Biosci. Rep. 15:1995;47-53.
133. Hui S.W., Langner M., Zhao Y.L., Ross P., Hurley E., Chan K. The role of helper lipids in cationic liposome-mediated gene transfer. Biophys. J. 71:1996;590-599.
134. Farhood H., Serbina N., Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta. 1235:1995;289-295.
135. Simberg D., Danino D., Talmon Y., Minsky A., Ferrari M.E., Wheeler C.J., Barenholz Y. Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. J. Biol. Chem. 276:2001;47453-47459.
136. Li S., Rizzo M.A., Bhattacharya S., Huang L. Characterization of cationic lipid-protamin-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 5:1998;930-937.
137. Wang J., Guo X., Xu Y., Barron L., Szoka F.C. Jr. Synthesis and characterization of long chain alkyl acyl carnitine esters. Potentially biodegradable cationic lipids for use in gene delivery. J. Med. Chem. 41:1998;2207-2215.
138. Hong K., Zheng W., Baker A., Papahadjopoulos D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett. 400:1997;233-237.
139. Hafez I.M., Maurer N., Cullis P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8:2001;1188-1196.
140. Litzinger D.C., Huang L. Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. Biochim. Biophys. Acta. 1113:1992;201-227.
141. Gao X., Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry. 35:1996;1027-1036.
142. Li S., Huang L. Novel lipidic vectors for gene transfer. Huang L., Hung M.C., Wagner E. Nonviral Vectors for Gene Therapy. 1999;289-309 Academic Press, San Diego.
143. Tan Y., Whitmore M., Li S., Frederik P., Huang L. LPD nanoparticles-novel nonviral vector for efficient gene delivery. Methods Mol. Med. 69:2002;73-81.
144. Ueno N.T., Bartholomeusz C., Xia W., Anklesaria P., Bruckheimer E.M., Mebel E., Paul R., Li S., Yo G.H., Huang L., Hung M.C. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res. 62:2002;6712-6716.
145. Sorgi F.L., Bhattacharya S., Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther. 4:1997;961-968.
146. Seville P.C., Kellaway I.W., Birchall J.C. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J. Gene Med. 4:2002;428-437.
147. Li B., Li S., Tan Y., Stolz D.B., Watkins S.C., Block L.H., Huang L. Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. J. Pharm. Sci. 89:2000;355-364.
148. Li S., Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4:1997;891-900.
149. Nikitin A.Y., Juarez-Perez M.I., Li S., Huang L., Lee W.H. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3916-3921.
150. Arangoa M.A., Duzgunes N., Tros de Ilarduya C. Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin- lipoplexes. Gene Ther. 10:2003;5-14.
151. Leone P., Janson C.G., Bilaniuk L., Wang Z., Sorgi F., Huang L., Matalon R., Kaul R., Zeng Z., Freese A., McPhee S.W., Mee E., During M.J., Bilianuk L. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann. Neurol. 48:2000;27-38.